PHILADELPHIA, Pa, February 22, 2021 – PolyCore Therapeutics LLC, a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders, today announced that Christopher M. Cashman, former chairman and chief executive officer of Marinus Pharmaceuticals, Inc., has been elected to PolyCore’s board of directors, effective February 19, 2021. “We… Read More


PHILADELPHIA, Pa, August 20, 2020 — PolyCore Therapeutics LLC, a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders, today announced that it has been awarded a $1.5 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to advance preclinical studies… Read More


PHILADELPHIA, Pa, July 20, 2020 — PolyCore Therapeutics LLC, a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative disorders, today announced the appointment of Kelly Beck as Chief Executive Officer and Board Director. “Kelly brings extraordinary skills and experience to PolyCore”, said Jim Harris, PolyCore Therapeutics’s Chairman of… Read More